Overview

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease. The long-term safety and tolerability of the rotigotine transdermal patch will also be evaluated.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
UCB Pharma
Treatments:
N 0437
Rotigotine
Criteria
Inclusion Criteria:

- Completion of trial SP889

Exclusion Criteria:

- Ongoing serious adverse event assessed as related to trial medication